List of Edarbi drug patents

Edarbi is owned by Azurity.

Edarbi contains Azilsartan Kamedoxomil.

Edarbi has a total of 3 drug patents out of which 0 drug patents have expired.

Edarbi was authorised for market use on 25 February, 2011.

Edarbi is available in tablet;oral dosage forms.

Edarbi can be used as treatment of hypertension.

The generics of Edarbi are possible to be released after 26 March, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(1 year, 11 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(5 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in